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ABSTRACT 
Objective: The objective of the current study was to elucidate the 3D pharmacophoric features of benzothiadiazine derivatives that are crucial for 
inhibiting Hepatitis C virus (HCV) Non-structural protein 5B (NS5B) and quantifying the features by building an atom based 3D quantitative 
structure-activity relationship (3D QSAR) model.  
Methods: Generation of QSAR model was carried out using PHASE 3.3.  
Results: A five-point pharmacophore model with two hydrogen bond acceptors, one negative ionization potential and two aromatic rings (AANRR) 
was found to be common among a maximum number of benzothiadiazine based NS5B inhibitors. A statistically significant 3D QSAR model was 
obtained from AANRR.6 which had correlation-coefficient (R2) value of 0.924, cross-validated correlation-coefficient (Q2) of 0.774, high Fisher ratio 
of 138 and low root mean square standard error (RMSE=0.29). There is another parameter, Pearson’s R, its value emphasizes correlation between 
predicted and observed activities of the test set. For the current model, Pearson’s R-value is 0.90, hence underlining the good quality of the model. 
The present study suggests that nitrogen atom of benzothiadiazine sulfamide ring, oxyacetamide group attached to C7 carbon of benzothiadiazine 
and sulfonamide oxygens are crucial for NS5B inhibitory activity. Prediction of activities of hit drugs generated in earlier research suggests that 
Aprepitant (Phase predicted activity: 6.9) could be a potential NS5B inhibitor. 
Conclusion: This 3D QSAR model developed was statistically good and can be used to predict the activities of newly designed NS5B inhibitors and 
virtual screening as well. Predict the activities of newly designed NS5B inhibitors and virtual screening as well. 
Keywords: Pharmacophore, QSAR, NS5B, HCV, Benzothiadiazine, Inhibitor 




Hepatitis C virus (HCV) Non-structural protein 5B (NS5B) is an RNA 
dependent RNA polymerase enzyme essential for viral genome 
replication. NS5B is an intensely pursued target for the development 
of Hepatitis C therapies, as it is the key enzyme in viral replication 
conserved among all the genotypes [1, 2]. NS5B is 591 amino acids 
long last 21 amino acids at C-terminal end function as membrane 
anchor and hence NS5B is also classified under tail anchor proteins. 
NS5B can be available in a full-length form and truncated form. 
Truncated form NS5B∆55: lacks 55 amino acids extending beyond 
the C-terminal 21 amino acids (a portion of the active site). 
Truncated form NS5B∆21: lacks C-terminal 21 amino acid tail [3, 4]. 
NS5B synthesises complementary–Ve stranded RNA from+Ve 
stranded RNA template. RNA replication occurs through either 
primer-dependent elongation or de novo initiation [5]. 
From the NS5B crystal structure, it was found that the structure of 
the enzyme resembles the shape of an encircled right hand and has 3 
domains, namely thumb, finger and palm. The thumb domain and 
finger domain are bridged by two loops namely ∆1 loop and ∆2 loop. 
NS5B has four allosteric sites and one active site [6, 7]. The thumb 
domain has two allosteric sites, one located at the apex of ∆ 1 loop 
and other is adjacent to ∆1 loop. Third allosteric site is located in the 
palm domain in close proximity to active site [7, 8]. 
There are several classes of HCV NS5B inhibitors that target 
different binding sites of the enzyme and inhibit HCV replication: (i) 
nucleoside analogues, (ii) pyrophosphate (PPi) analogues, (iii) non-
nucleoside inhibitors. Nucleoside analogues bind to the active site of 
the enzyme by competing with the natural nucleotide triphosphate 
(NTP) counterparts for incorporation. In contrast, the non-
nucleoside inhibitors bind to allosteric sites and inhibit RNA 
synthesis at initiation stage. The pyrophosphate analogues mimic 
the PPi released during nucleotidyl transfer [9]. Many compounds 
targeting active and allosteric sites (Direct Acting Anti-virals) are in 
clinical development and till date, only active site inhibitors were 
launched in the market. Sofosbuvir is the breakthrough drug in the 
HCV research with pan-genotypic activity and good safety profile 
and is effective against cirrhosis as well [10]. Since then many 
Sofosbuvir based combination therapies were launched in the 
market. However, still there is a need for cost-effective therapies 
with short treatment duration (<8 w) and should be beneficial for 
niche patient population resistant to earlier therapies and those 
with renal failure as a comorbidity [11]. 
In the present study, a pharmacophore modelling and 3D-QSAR 
analysis was carried out using currently available NS5B inhibitors 
binding to Palm I site of the enzyme which could facilitate the 
activity prediction of newly identified Palm I inhibitors, to indentify 
novel NS5B inhibitors through virtual screening and help in optimizing 
identified hits. QSAR technique is widely used in ligand-based drug 
designing especially for lead optimization and identification of variable 
and potent compounds through virtual screening. QSAR quantifies the 
relationship between structural features of the compounds and 
biological activities. Herein an atom based QSAR model was built 
based on pharmacophore features generated using a group of 
benzothiadiazine derivatives binding to Palm I site of NS5B and tested 
under same experimental conditions. PHASE module of Schrodinger, 
New York was used for this analysis [12]. 
MATERIALS AND METHODS 
Dataset 
For the generation of pharmacophore based 3D-QSAR hypothesis, a 
set of 89 unique benzothiadiazine derivatives tested under same 
experimental conditions and with well-defined NS5B inhibitory 
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activity were selected [13-15] (table 1). All the 89 molecules were 
optimized and energy minimized using LigPrep module of 
Schrödinger. Ligand preparation involves the addition of hydrogens, 
adjusting bond orders, generation of stereoisomers, ionization states 
and tautomers, calculation of the energy of the molecule using 
OPLS_2005 force field, conversion of 2D to low energy 3D structure. 
The prepared ligands were subjected to conformation analysis 
where conformers were generated using ConfGen module 
implemented in Schrödinger which uses Monte Carlo simulations. 
Conformer with the lowest energy was selected for each of the 89 
molecules and loaded to Phase 3.3 model for the development of 
pharmacophore model. 
 
Table 1: Dataset of benzothiadiazine derivatives used for building 3D QSAR model 
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Creation of pharmacophore sites and common pharmacophore 
hypothesis 
As the 3D-QSAR relies on the relationship between free energy 
change and equilibrium constant (ΔG °=-2.3RTlogKc), the data for 
QSAR model generation should be expressed in terms of free energy 
changes occurring during biological response [16]. 
ΔG °=-2.3RTlog10Kc 
ΔG is Gibb’s free energy, R is gas constant, T is temperature, Kc is 
equilibrium constant which is the ratio of the concentration of 
products and concentration of reactants. When measuring 
concentration values under equilibrium conditions, the concentration 
of the compound should be expressed as the inverse logarithm of 
compound concentration. The change is Gibb’s free energy is directly 
proportional to the inverse logarithm of compound concentration [16]. 
ΔG ° =-2.3RTlog10Kc = log1/[S] 
Where [S] is compound concentration 
Hence, the in vitro inhibitory concentration (IC50) values of 89 
molecules were converted to corresponding pIC50 (log1/IC50) values 
and used as dependent variable. The entire dataset is divided into 
actives and inactives based on activity threshold value (7.8) which 
was derived from dataset activity distribution (ranging from 6.0 to 
8.3). All the ligands with activity value greater than threshold value 
were categorized as active (31 molecules) and those with activity 
value less than threshold value were considered inactive (58 
molecules). Active ligands were chosen for identification of 
pharmacophore features, their frequency of occurrence and creation 
of pharmacophore sites points. The common pharmacophore 
hypothesis (CPH) was identified based on these site points using 
tree-based partitioning technique [17].  
First, variant list of pharmacophore hypotheses was generated using 
the features and site points where the criteria were, a hypothesis 
should have minimum and maximum of 5 site points and must 
match at least 25/31 actives. Variant hypothesis not present in any 
of the ligands was filtered out and those common among maximum 
ligand molecules were picked for scoring and ranking. The best 
candidate CPH, which conveys 3D chemical characteristics that are 
critical for binding was selected for building the 3D-QSAR model. 
Building 3D-QSAR model 
3D-QSAR model was generated using the best candidate hypothesis 
selected based on scoring parameters. For a model generation, the 
entire data set was divided into a training set (70%) and test set 
(30%) in a random manner using “Automated Random Selection” 
option available in PHASE module [18]. PHASE has two approaches 
for building 3D-QSAR model–pharmacophore based and atom based 
approach. In pharmacophore based QSAR, only pharmacophore 
features are considered and not whole ligand features, hence, in this 
study, an atom based QSAR model was built. In atom based QSAR 
modelling, each molecule is considered as a set of Van Der Waal’s 
spheres (each atom corresponds to a sphere). Each Sphere is placed 
into one of the six categories-Hydrogen bond donor (Hydrogens 
attached to polar atoms), hydrophobic atom (carbons, halogens and 
hydrogens attached to them), Negative ionic atom (atoms with 
negative charge), Positive ionic atom (atoms with positive charge), 
electron withdrawing atoms (Polar atoms) and miscellaneous atoms 
(Other types of atoms). Van der Waal’s spheres of training set 
molecules are placed into a grid of cubes and each cube is allocated 
zero or more bits depending on different types of atoms occupying 
the cube. This occupation pattern is used to create partial least 
squares (PLS) QSAR models which can be used as an independent 
variable for QSAR model generation. The number of PLS factors in 
each model can be 1/5 of the training set molecules. 
RESULTS AND DISCUSSION 
NS5B inhibitors offer therapeutic potential for treatment of hepatitis 
C. Several compounds binding to allosteric sites of the enzyme were 
discovered, however, none of them was launched yet. In an attempt 
to identify more potent inhibitors binding to Palm I allosteric site of 
the enzyme, pharmacophoric characteristic features that are crucial 
for binding to NS5B allosteric site were identified using already 
reported NS5B inhibitors. From a set of 31 actives among 89 
benzothiadiazine analogues, a total of 102 variant hypotheses were 
generated. From the variant list, CPHs were identified and include 
AANRR which comprise pharmacophores of 22 ligands–AANRR (22), 
AAARR (15), AAANR (11), AARRR (10), AHNRR (10), and AAPRR (10).  
The CHPs were scored and ranked to identify the best candidate 
hypothesis. The scoring algorithm includes alignment with actives, 
the site points and vectors, volume overlap, selectivity, number of 
active ligands matched, relative conformational energy and activity 
[17]. Also, these pharmacophore hypotheses should discriminate 
between actives and inactives. A pharmacophore hypothesis 
comprises information on critical sites required for binding of 
actives and also sites which are preventing inactive from binding.  
To identify the pharmacophore models with more active and less 
inactive features, they were aligned with inactives and scored (In 
active). The survival score was adjusted by subtracting survival 
score of active with survival score of inactive (Survival (inactive)). 
 The hypothesis with maximum adjusted survival score is more 
preferred. After analysis of scores, the CPHs were ranked and best 
candidate hypothesis was selected which was used for building the 
3D-QSAR model. The best candidate hypothesis along with its 
corresponding scores is summarized in table 2. 
 
 
Table 2: Best candidate hypothesis along with scoring parameters 
ID Survival Survival (Inactive) Site vector Volume Selectivity #Matches Energy Activity Inactive 
AANRR.6 3.668 1.401 0.95 0.996 0.726 2.249 25 0 7.886 2.267 
Survival–A weighed combination of Site, vector and volume, larger the survival value better is the alignment of ligand over common 
pharmacophore, Survival (inactive)–Survival score of active with survival score of inactive subtracted, Site–this score determines how 
closely the site points are superimposed on the pharmacophore, Vector–Alignment score, Volume–Measurement of volume overlap in ligand 
and pharmacophore alignment, Selectivity–uniqueness of the pharmacophore to a particular ligand, #Match–number of actives fitting to the 
hypothesis, Energy–Relative energy of the reference ligand in kcal/mol, Activity–Relative activity of the reference ligand, Inactive–Survival 
score of inactive. 
 
The best candidate hypothesis AANRR.6 was associated with five-
point hypotheses and comprise of two hydrogen bond acceptors 
(pink sphere with arrows), negatively charged group (pink sphere), 
two aromatic rings (orange rings) (fig. 1A). When aligned with the 
molecule with maximum fitness score, the two oxygens of 
benzothiadizinyl ring occupied the hydrogen bond acceptor spheres; 
oxygen at C-2 position of quinolinone is engaged with a negatively 
charged sphere and aromatic rings were mapped to quinolinone and 
benzothiadizinyl rings (fig. 1B). Alignments of actives and inactives 
are shown in fig. 1C and D respectively. From fig. 1 we can easily 
identify that active ligand is having good alignment than an inactive 
one.
 




Fig. 1: Best common pharmacophore hypothesis: (A) Pharmacophore site points (B) Alignment of best fit molecule (CMPD-20) and site 
points (C) alignment of active ligands with CPH (D) alignment of inactive ligands with CPH 
 
The spatial arrangement of features along with distances and angles 
were depicted in fig. 2 A and B. AANRR.6 was selected for building an 
atom based 3D-QSAR model. For generating the 3D-QSAR model, the 
dataset was randomly divided into training set and test set. A five-
component PLS model with good statistics was generated using 62 
training set compounds and validated using 24 test set compounds. A 
PLS factor of five is used to generate the model as it was observed that 
there was a significant increment in statistics and predictivity with an 
increase in PLS factors. The pharmacophore hypothesis AANRR.6 
yielded a 3D QSAR model with good statistical scores. 
 
 
Fig. 2: Pharmacophore site distances (A) Pharmacophore site of angles (B) 
 
As suggested by many QSAR modellers the model should be verified 
by goodness of Fit (R2), robustness or internal predictivity (Q2) and 
external predictivity (validation using external chemical compounds 
that were never included in the training set even at least once during 
the model building) [19]. The aim of internal predictivity is 
preliminary model validation and to select more robust and 
predictive model whereas, the goal of external predictivity is to 
evaluate the predictive power of the developed model by using it 
against a set of completely unseen chemical structures. 
The model showed a good R2 value of 0.924, Fit value (F) =138, 
standard deviation, (SD) =0.24 for the training set. Lower value of 
standard deviation (SD) reflects a lesser deviation from biological 
data. The model was validated using the internal test set molecules 
and the validity of the model is expressed as cross-validated R2 (Q2) 
which is the characteristic of the predictive ability of the model. The 
Q2 value less than R2 and close to R2 indicate the good predictive 
ability of the model. Cross-validation was done using leave one out 
(LOO) method, where one molecule from the training set is left out 
(only once) and R is computed for the left out molecule using model 
generated with remaining training set molecules. Sometimes more 
than one molecule is left out at one time (leave many out (LMO)). 
The Q2 value (0.77) so obtained emphasizes the model generated is 
best with RMSE value of 0.299. The fit of the model can be 
determined by root-mean-squared error (RMSE), an error between 
the mean of experimental activities and predicted activities. Lower 
RMSE reflects good predictive quality of the model. The statistical 
results of atom based QSAR model built are summarized in table 3. 
 
Table 3: Statistical parameters of QSAR model built based on AANRR.6 
ID PLS Factors SD R2 F P RMSE Q2 Pearson-R 
AANRR.6 1 0.624 0.4805 55.5 4.278e-010 0.4617 0.4639 0.724 
2 0.4927 0.6821 63.3 2.08e-015 0.3975 0.6027 0.83 
3 0.3882 0.806 80.3 1.236e-020 0.3393 0.7105 0.857 
4 0.3503 0.8447 77.5 2.213e-022 0.3605 0.6733 0.839 
5 0.2475 0.9249 138 3.454e-030 0.2993 0.7748 0.908 
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The interaction between ligand and receptor active site is analyzed 
using QSAR visualization option in PHASE and the interaction is 
represented by clouded cubes where blue and red cubes represent 
favourable and unfavourable regions respectively. The pharma-
cophore hypothesis that yielded 3D-QSAR model is aligned with 
ligands and features essential for NS5B inhibitory activity were 
analyzed. The 3D-QSAR visualization for most active compound and 
least active compound were given in fig. 3 and fig. 4 respectively. 
 
 
Fig. 3: Visualization of QSAR Model in the context of the active compound (Compound 22) in the training set. A) Hydrogen bond feature B) 
Hydrophobic feature C) Electron withdrawing feature D) Combination of all the pharmacophoric features 
 
In the most active compound, positive correlation of H-Bond donor 
feature was seen at the nitrogen atom of benzothiadiazine sulfamide 
ring and the oxygen atom of oxyacetamide group attached to C7 
carbon. Benzothiadiazole analogues with oxyacetamide substitution 
at C7 position showed low micromolar inhibitory activity in the 1b 
replicon assay also it makes favourable hydrogen bonding with Asn 
291 [15]. The electron withdrawing atoms which are part of 
oxyacetamide group were also positively correlated with NS5B 
inhibitory activity. Among the hydrophobic groups present in the 
molecule, Quinoline ring is positively correlated with activity. 
Substitution of fluorine at C6 position of the quinolone ring has been 
shown to improve the cellular activity [20]. In the less active 
compound, nitrogen atoms of 5-hydroxy pyridazine ring (hydrogen 
bond donor) and benzyl moiety of benzothiadiazine ring 
(hydrophobic group) are negatively correlated with activity (fig. 4). 
This molecule was also lacking a substituent at the C7 position, 




Fig. 4: Visualization of QSAR model in the context of inactive compound (Compound 50) in the training set. A) Hydrogen bond feature B) 
hydrophobic feature C) electron withdrawing feature D) combination of all the pharmacophoric features 
 
Fitness graph of observed values Vs PHASE predicted values with 45° 
regression line are depicted in fig. 5. The Fitness graph emphasizes 
reasonably good alignment between experimental values and 
predicted values for more than 70% of the dataset molecules. 
Predicted activity values of training and test set molecules are 
furnished in table 4. 
 




Fig. 5: Fitness graph between observed and predicted values 
 
Table 4: Predicted activities of training and test set molecules 
S. No. Compound No QSAR set Observed activity Predicted activity Pharm set Fitness 
1 CMPD-1 Test 6.056 5.73 Inactive 1.54 
2 CMPD-2 Test 6.168 5.95 Inactive 1.52 
3 CMPD-3 Training 6.218 6.30 Inactive 2.12 
4 CMPD-4 Test 7.745 7.32 Inactive 2.99 
5 CMPD-5 Test 7.509 7.50 Inactive 2.95 
6 CMPD-6 Training 7.698 7.68 Inactive 2.29 
7 CMPD-7 Test 8.301 8.08 Active 2.60 
8 CMPD-8 Training 8.301 8.33 Active 2.61 
9 CMPD-9 Training 8.301 7.80 Active 2.62 
10 CMPD-10 Training 8.221 8.21 Active 2.54 
11 CMPD-11 Training 8.301 8.24 Active 1.05 
12 CMPD-12 Training 8.301 8.25 Active 1.04 
13 CMPD-13 Training 8.301 8.28 Active 1.00 
14 CMPD-14 Training 8.301 8.35 Active 1.01 
15 CMPD-15 Test 7.920 7.78 Active 1.04 
16 CMPD-16 Test 7.795 7.55 Inactive 1.10 
17 CMPD-17 Training 6.673 7.08 Inactive 1.10 
18 CMPD-18 Training 8.221 7.91 Active 2.30 
19 CMPD-19 Test 7.522 7.97 Inactive 3.00 
20 CMPD-20 Training 7.886 7.99 Active 3.00 
21 CMPD-21 Training 8.301 8.52 Active 2.69 
22 CMPD-22 Training 8.301 8.22 Active 2.52 
23 CMPD-23 Training 8.154 8.14 Active 1.03 
24 CMPD-24 Training 7.327 7.23 Inactive 1.06 
25 CMPD-25 Training 8.000 7.92 Active 2.74 
26 CMPD-26 Test 7.698 7.27 Inactive 1.06 
27 CMPD-27 Training 7.886 7.76 Active 2.95 
28 CMPD-28 Training 7.494 7.45 Inactive 2.58 
29 CMPD-29 Training 6.698 7.03 Inactive 1.06 
30 CMPD-30 Test 7.602 7.48 Inactive 2.67 
31 CMPD-31 Training 8.301 8.44 Active 2.60 
32 CMPD-32 Training 7.795 7.99 Inactive 2.67 
33 CMPD-33 Training 6.539 6.61 Inactive 2.22 
34 CMPD-34 Training 6.168 6.13 Inactive 1.52 
35 CMPD-35 Training 6.010 6.89 Inactive 2.31 
36 CMPD-36 Training 6.111 5.83 Inactive 1.55 
37 CMPD-37 Test 6.540 5.97 Inactive 2.41 
38 CMPD-38 Training 6.137 5.71 Inactive 2.45 
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39 CMPD-39 Test 6.559 6.57 Inactive 2.13 
40 CMPD-40 Training 6.879 6.93 Inactive 2.29 
41 CMPD-41 Test 6.056 6.04 Inactive 1.55 
42 CMPD-42 Training 5.816 5.82 Inactive 2.46 
43 CMPD-43 Training 6.218 6.15 Inactive 1.53 
44 CMPD-44 Training 6.698 6.83 Inactive 2.50 
45 CMPD-45  5.520  Inactive  
46 CMPD-46 Test 7.244 7.31 Inactive 2.53 
47 CMPD-47 Test 7.698 7.35 Inactive 2.87 
48 CMPD-48 Training 7.795 7.64 Inactive 2.95 
49 CMPD-49 Training 7.292 7.24 Inactive 2.31 
50 CMPD-50 Training 5.306 5.88 Inactive 2.66 
51 CMPD-51 Training 5.476 5.05 Inactive 1.03 
52 CMPD-52    Inactive  
53 CMPD-53 Training 6.879 7.06 Inactive 2.66 
54 CMPD-54 Test 7.318 7.56 Inactive 2.66 
55 CMPD-55 Training 8.045 7.82 Active 2.51 
56 CMPD-56 Test 7.657 7.69 Inactive 2.52 
57 CMPD-57 Test 7.920 8.30 Active 2.85 
58 CMPD-58 Training 8.301 8.35 Active 2.51 
59 CMPD-59 Training 7.920 7.92 Active 2.50 
60 CMPD-60 Training 8.301 8.05 Active 2.51 
61 CMPD-61 Training 7.443 7.98 Inactive 2.86 
62 CMPD-62 Training 8.301 8.07 Active 2.87 
63 CMPD-63  6.694  Inactive  
64 CMPD-64 Training 8.221 8.41 Active 2.44 
65 CMPD-65 Training 8.301 8.21 Active 2.49 
66 CMPD-66 Training 8.301 7.98 Active 2.52 
67 CMPD-67 Training 7.769 7.65 Inactive 2.57 
68 CMPD-68 Training 7.619 7.57 Inactive 2.57 
69 CMPD-69 Training 8.301 8.28 Active 2.96 
70 CMPD-70 Training 7.744 7.76 Inactive 2.90 
71 CMPD-71 Training 8.301 7.88 Active 2.94 
72 CMPD-72 Training 6.164 6.34 Inactive 2.90 
73 CMPD-73 Test 6.847 7.08 Inactive 2.95 
74 CMPD-74 Test 8.221 7.70 Active 2.91 
75 CMPD-75 Training 8.096 7.76 Active 2.90 
76 CMPD-76 Test 7.638 7.24 Inactive 0.99 
77 CMPD-77 Training 8.154 7.82 Active 2.95 
78 CMPD-78 Training 6.991 7.10 Inactive 2.19 
79 CMPD-79 Training 7.346 7.60 Inactive 2.96 
80 CMPD-80 Training 7.187 7.34 Inactive 2.24 
81 CMPD-81 Training 6.896 6.92 Inactive 2.35 
82 CMPD-82 Test 7.259 7.61 Inactive 1.08 
83 CMPD-83 Training 6.847 7.46 Inactive 2.96 
84 CMPD-84 Training 6.623 6.81 Inactive 2.35 
85 CMPD-85 Test 7.301 7.46 Inactive 3.00 
86 CMPD-86 Training 7.244 7.50 Inactive 2.31 
87 CMPD-87 Training 6.761 7.08 Inactive 2.23 
88 CMPD-88 Test 7.119 7.04 Inactive 2.23 
89 CMPD-89 Training 7.585 7.50 Inactive 3.00 
 
There has been a debate on QSAR model validation topic over the 
past decade and was the subject of discussion in scientific 
communities [21, 22]. The consensus was that both cross-validation 
(internal validation) and external validation are philosophically 
different approaches and both are required to characterize the 
model [19]. As per organisation for economic co-operation and 
development (OECD) Principles, the QSAR model generated should 
be verified for the goodness of fit, applicability domain, robustness 
and predictive capability [23].  
In internal validation, the model will be validated using test set 
molecules that were also part of training set during multiple 
iterations of model generation. Internal Validation determines the 
statistical robustness of the model and this preliminary validation is 
required to proceed for external validation. In external validation, a 
new set of molecules (prediction set) which were never part of 
training set during model development will be used for verifying the 
model. The prediction set can be either separated from the dataset 
selected before the model generation or collated from the literature 
after model generation. The number of molecules in the prediction 
set should be 10–20% of the dataset (both training and test set 
molecules) used for model generation.  
External validation demonstrates the predictive power of the model. 
In the current study, though the QSAR model was validated using 
cross-validation, this validation is not sufficient to demonstrate the 
predictive capability of the model (24).  
Hence, the generated model was also validated using the prediction 
set comprising 10 benzothiadiazine analogues [25]. The activity 
values predicted with 3D QSAR model built using AANRR.6 were 
given the table 5. For most of the compounds, the observed values 
were aligned with predicted values. 
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Table 5: Predicted and experimental values of external dataset comprising benzothiadiazine analogues 
































The robustness and predictive power of the model were proved 
through internal and external validation. This model was used to 
predict the NS5B inhibitory potential of the drugs (Aprepitant, 
Doripenem and Argathroban) that showed desired binding 
interactions with residues of the binding pocket [26]. It was found 
that the predicted activities of only Aprepitant are in line the 
activities of the existing active palm I inhibitors. The details of phase 
predicted activities were furnished in table 6. Structural features of 
Aprepitant fit with 4 (A2, A3, R14 and N11) out of 5 pharmacophoric 
site points. The genomics analysis performed earlier also 
emphasized desired overlap between HCV pathophysiology and 
Aprepitant effects [26]. 
 
Table 6: Phase predicted activities of aprepitant 












Aprepitant 4 6.91 6.84 6.95 6.90 6.93 
 
HCV research has gained momentum in the recent past. Many 
hepatitis C drugs were launched in the market since 2011 and 
sofosbuvir is considered as a breakthrough drug. However, in 
spite of tremendous progress in hepatitis C drug discovery still 
there exist an unmet medical need in this therapeutic area. Also, 
the marketed NS5B inhibitors act by binding to the active site 
and none of the NS5B allosteric inhibitors was launched yet. In 
order to strengthen the pipeline of NS5B inhibitors targeting 
palm I site (present close to active site), a 3D QSAR model was 
generated in the present study that can be used to optimize 
existing NS5B inhibitors binding to palm I, to predict NS5B 
inhibitory activity of new molecular entities and also to identify 
new NS5B inhibitors through virtual screening. An Atom-based 
QSAR model was built using pharmacophoric features common 
among benzothiadiazine derivatives.  
The common pharma-cophore hypothesis AANRR.6 is the best 
hypothesis with survival score of 3.668. The best candidate 
hypothesis AANRR.6 has two hydrogen bond acceptors, one 
negative ionization potential and two aromatic rings. The 3D 
QSAR model built using AANRR.6 showed good statistical scores 
(R2 = 0.924, Q2value 0.774) and prediction power was 
demonstrated using external dataset. Prediction of NS5B 
inhibitory activity of drugs identified in the earlier work 
emphasized the fact that Aprepitant could be a potential 
inhibitor. 
CONCLUSION 
The 3D QSAR model emphasized the positive correlation of 
nitrogen atom of benzothiadiazine sulfamide ring, oxyacetamide 
group attached to C7 carbon of benzothiadiazine and 
sulfonamide oxygens with NS5B inhibitory activity. NS5B 
inhibitory potential predicted by 3D-QSAR model emphasizes 
the Aprepitant as a potential inhibitor but needs to be further 
evaluated under in vitro conditions. 
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